NICE has recommended in draft guidance that three thyroid cancer treatments can receive regular NHS funding, finally approving a drug from Eisai after a delay of more than two years because it ...

NICE has rejected Bayer's Nexavar and Eisai's Lenvima in thyroid cancer, saying in draft guidance that neither is cost-effective against the disease. Bayer's drug has been available on the CDF ...